NSTEMI and supraventricular tachycardia post-chemotherapy: a rare cardiotoxic complication

Abstract

Chemotherapy-induced myocardial infarction (MI) is an exceptionally rare but significant complication of cancer treatment. This report discusses a case of a 52-year-old patient with breast cancer who developed non-ST elevation myocardial infarction (NSTEMI) three days after receiving doxorubicin and cyclophosphamide that were her 5th cycle of chemotherapy. The diagnosis was supported by elevated troponin levels, echocardiographic findings, and electrocardiography (ECG) showing supraventricular tachycardia (SVT) with aberrancy, which was treated with cardioversion. This case highlights the importance of distinguishing chemotherapy-induced MI from other cardiotoxic effects and emphasizes the need for vigilant cardiac monitoring during cancer therapy.